Form D · Biotechnology
Arcturus Therapeutics Ltd.
San Diego, CA · CIK 0001566049
Offering snapshot reported Jan 4, 2018 · SEC filing
- Reported sold
- $67.8M Offering amount: $67.8M
- Investors reported
- 82 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 15, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 4, 2018 | Initial | $67,776,096 | No comparison | 82 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $950K
- Finders' fees
- $0
- Form D file number
- 021-302301
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| None | None | Ladenburg Thalmann & Co. Inc. · CRD 505 |
Source: Form D, filed Jan 4, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Pad Chivukula | Director, Executive |
| Stuart Collinson | Director |
| Daniel Geffken | Director |
| Joseph E Payne | Director, Executive |
| David Shapiro | Director |
| Orli Tori | Director |
| Craig Willett | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
10628 Science Center Drive, Suite 200
San Diego, CA, 92121
San Diego, CA, 92121